ONCT Oncternal Therapeutics Inc: Earnings per share for the last 12 months

Oncternal (ONCT) - corporate logo

Oncternal Therapeutics (ONCT) relies on outsourcing for production and research to minimize capital expenditures. The YoY EPS trend over the last 12 months confirms this flexibility, while the value of 10.80 reflects the metric's balance. Growth prospects depend on the success of CAR-T programs and licenses; however, a revenue deficit and depleting reserves are creating significant financial pressure on the company.

Oncternal (ONCT) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

ONCT (Oncternal Therapeutics Inc): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:ONCT Oncternal
Flagship merchandise of Oncternal Therapeutics, Inc.

Oncternal Therapeutics (ONCT) operates in the protected innovative medicine sector, which remains independent of global macroeconomic fluctuations. This metric calculates the rolling annual growth of net income per share over the last twelve months. It allows investors to filter out market noise and assess the real operational efficiency of the business. The current value of 10.80 confirms the financial stability of the issuer's development strategy. Analyzing the TTM YoY earnings per share trend helps identify the risks of future drawdowns in advance.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months nucana.com|CMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CYCC|Net earnings per share (EPS TTM) G1 Therapeutics Inc. (GTHX)|Earnings per share for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months